Continuing immune checkpoint inhibitors beyond progression versus switching to non-ICI therapy in advanced gastric cancer: a real-world study - Top-Institutions - MDSpire

Continuing immune checkpoint inhibitors beyond progression versus switching to non-ICI therapy in advanced gastric cancer: a real-world study

  • By

  • Guangxi Wang

  • Xiaonan Lu

  • Yunmei Wang

  • Xiang Wang

  • Ruoxuan Wang

  • Jinyu Jia

  • June 3, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Comprehensive Cancer Center
    Comprehensive Cancer Center

    Location Unknown, Location Unknown

    Key Differentiators

    • Oncology

  • #2

    University of Alabama
    University of Alabama

    Birmingham, AL

    Key Differentiators

    • Oncology

  • #3

    Rigshospitalet, Copenhagen University Hospital
    Rigshospitalet, Copenhagen University Hospital

    Copenhagen, Denmark

    Key Differentiators

    • Oncology

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology

  • #5

    Moffitt Cancer Center
    Moffitt Cancer Center

    Tampa, FL

    Key Differentiators

    • Oncology

Original Source(s)

Continuing immune checkpoint inhibitors beyond progression versus switching to non-ICI therapy in advanced gastric cancer: a real-world study

  • by Guangxi Wang, Xiaonan Lu, Yunmei Wang, Xiang Wang, Ruoxuan Wang, Jinyu Jia

  • June 3, 2026

Related Content

Automated bone marrow cell classification using ensemble learning: performance, generalization, and clinical interpretability

Case Report: Cytokeratin-positive interstitial reticulum cell tumor with HLA loss of heterozygosity

Direct comparison of efficacy of combining ivermectin versus five first-line chemotherapy drugs with recombinant methioninase against colon-cancer cells